Stocks and Investing
Stocks and Investing
Fri, February 2, 2024
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
[ Fri, Feb 02nd 2024
] - WOPRAI
Thu, February 1, 2024
[ Thu, Feb 01st 2024
] - WOPRAI
[ Thu, Feb 01st 2024
] - WOPRAI
[ Thu, Feb 01st 2024
] - WOPRAI
[ Thu, Feb 01st 2024
] - WOPRAI
[ Thu, Feb 01st 2024
] - WOPRAI
[ Thu, Feb 01st 2024
] - WOPRAI
[ Thu, Feb 01st 2024
] - WOPRAI
[ Thu, Feb 01st 2024
] - WOPRAI
[ Thu, Feb 01st 2024
] - WOPRAI
[ Thu, Feb 01st 2024
] - WOPRAI
[ Thu, Feb 01st 2024
] - WOPRAI
[ Thu, Feb 01st 2024
] - WOPRAI
[ Thu, Feb 01st 2024
] - WOPRAI
[ Thu, Feb 01st 2024
] - WOPRAI
Mike Matson Maintained (SRDX) at Strong Buy with Increased Target to $47 on, Feb 1st, 2024
Mike Matson of Needham, Maintained "Surmodics, Inc." (SRDX) at Strong Buy with Increased Target from $44 to $47 on, Feb 1st, 2024.
Mike has made no other calls on SRDX in the last 4 months.
There is 1 other peer that has a rating on SRDX. Out of the 1 peers that are also analyzing SRDX, 0 agree with Mike's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mike
- Michael Petusky of "Barrington Research" Maintained at Buy with Increased Target to $71 on, Thursday, November 9th, 2023
Contributing Sources